CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT07506109
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:01.885086+00:00
- Published At
- 2026-04-07T00:00:00+00:00
- Record Updated At
- 2026-04-07
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["BRAF V600E", "Colorectal Cancer", "Sintilimab", "MSS (Microsatellite Stable)", "Cetuximab", "Dabrafenib", "Ipilimumab N01"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-07"- protocolSection.identificationModule.nctId
"NCT07506109"- protocolSection.identificationModule.officialTitle
"A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.